Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$5.58 USD
-0.42 (-7.00%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $5.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.58 USD
-0.42 (-7.00%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $5.58 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum B VGM
Zacks News
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to Buy
by Zacks Equity Research
Oncobiologics (OTLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
by Zacks Equity Research
Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More
by Zacks Equity Research
Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
by Zacks Equity Research
Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.
Should You Buy Outlook Therapeutics (OTLK) Ahead of Earnings?
by Zacks Equity Research
Outlook Therapeutics (OTLK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Oncobiologics, Inc. (OTLK) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Oncobiologics, Inc. (OTLK) delivered earnings and revenue surprises of -83.33% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Oncobiologics, Inc. (OTLK) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Oncobiologics, Inc. (OTLK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.
Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%
by Zacks Equity Research
Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Hottest Wall Street Stories: What's Up, What's Down
by Sweta Killa
Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.